Diversity-oriented synthesis yields novel multistage antimalarial inhibitors

No Thumbnail Available
File version
Author(s)
Kato, Nobutaka
Comer, Eamon
Sakata-Kato, Tomoyo
Sharma, Arvind
Sharma, Manmohan
Maetani, Micah
Bastien, Jessica
Brancucci, Nicolas M
Bittker, Joshua A
Corey, Victoria
Clarke, David
Derbyshire, Emily R
Dornan, Gillian L
Duffy, Sandra
Eckley, Sean
Itoe, Maurice A
Koolen, Karin MJ
Lewis, Timothy A
Lui, Ping S
Lukens, Amanda K
Lund, Emily
March, Sandra
Meibalan, Elamaran
Meier, Bennett C
McPhail, Jacob A
Mitasev, Branko
Moss, Eli L
Sayes, Morgane
Van Gessel, Yvonne
Wawer, Mathias J
Yoshinaga, Takashi
Zeeman, Anne-Marie
Avery, Vicky M
Bhatia, Sangeeta N
Burke, John E
Catteruccia, Flaminia
Clardy, Jon C
Clemons, Paul A
Dechering, Koen J
Duvall, Jeremy R
Foley, Michael A
Gusovsky, Fabian
Kocken, Clemens HM
Marti, Matthias
Morningstar, Marshall L
Munoz, Benito
Neafsey, Daniel E
Sharma, Amit
Winzeler, Elizabeth A
Wirth, Dyann F
Scherer, Christina A
Schreiber, Stuart L
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2016
Size
File type(s)
Location
License
Abstract

Antimalarial drugs have thus far been chiefly derived from two sources—natural products and synthetic drug-like compounds. Here we investigate whether antimalarial agents with novel mechanisms of action could be discovered using a diverse collection of synthetic compounds that have three-dimensional features reminiscent of natural products and are underrepresented in typical screening collections. We report the identification of such compounds with both previously reported and undescribed mechanisms of action, including a series of bicyclic azetidines that inhibit a new antimalarial target, phenylalanyl-tRNA synthetase. These molecules are curative in mice at a single, low dose and show activity against all parasite life stages in multiple in vivo efficacy models. Our findings identify bicyclic azetidines with the potential to both cure and prevent transmission of the disease as well as protect at-risk populations with a single oral dose, highlighting the strength of diversity-oriented synthesis in revealing promising therapeutic targets.

Journal Title
Nature
Conference Title
Book Title
Edition
Volume
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical pharmacology and therapeutics
Persistent link to this record
Citation
Collections